Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meeting

Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.

The presentation, “Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial” will be featured as part of the Paper Session, on April 25, 2023 between 12:30 pm to 12:45 pm MDT, by Eyal Banin, MD, PhD, Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology at Hadassah-Hebrew University Medical Center (presentation number 2826, session number 331). RG6501 (OpRegen) is a retinal pigment epithelium cell transplant therapy currently in development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). It is being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD (ClinicalTrials.gov Identifier: NCT05626114).